EC Approves Upadacitinib in Pediatric JIA on Phase 1 Data: Regulatory Win, HTA Battle Ahead

EC Approves RINVOQ for Pediatric Polyarticular Juvenile Idiopathic Arthritis

AbbVie announced that the European Commission (EC) has approved RINVOQ (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older. This approval is for those who have responded inadequately to, or are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs). The approval is supported by data from the open-label Phase 1 SELECT-YOUTH study, which evaluated pharmacokinetics, efficacy, safety, and tolerability in 122 patients aged 2 to <18 years, as well as data from adults with rheumatoid arthritis. A new 1 mg/mL oral solution of RINVOQ was also approved, alongside the 15 mg tablet, for use as monotherapy or in combination with methotrexate.

• The European Commission's approval expands RINVOQ's indications in the EU to include active pJIA in children aged two years and older. This specifically targets patients with polyarticular rheumatoid factor positive (RF+) or negative (RF-), or extended oligoarticular pJIA, who have not adequately responded to or are intolerant of existing DMARDs. The approval includes both a 15 mg tablet and a new weight-based 1 mg/mL oral solution, offering flexible administration options.
• The SELECT-YOUTH study demonstrated significant efficacy, with 66.4% of patients achieving an ACR pediatric 70 response at Week 12, improving to 79.5% by Week 48. Clinical remission (JADAS27-CRP ≤1) was achieved by 23.0% at Week 12 and 43.4% at Week 48. Additionally, functional ability, measured by C-HAQ, improved with a mean change of −0.46 at Week 12 and −0.64 at Week 48, alongside pain score improvements.
• The study identified no new safety risks for RINVOQ in pediatric pJIA patients. The rate of treatment-emergent adverse events (TEAEs) was 499.6 events per 100 patient-years (E/100 PY), with serious adverse events at 10.2 E/100 PY. Importantly, no cases of major cardiovascular or thrombotic events, malignancies, or deaths were reported during the study period, and no negative impact on growth or development was observed, reinforcing its potential as a safe and effective oral systemic treatment.

Addressing Unmet Needs in Pediatric Polyarticular JIA

Polyarticular JIA remains a therapeutically challenging subtype, with recent literature highlighting persistent gaps in early identification, treatment optimization, and long-term disease management. Several distinct populations and clinical scenarios continue to drive unmet need across the disease course.

• MTX non-responders with uveitis: Among 99 JIA-associated uveitis patients treated with methotrexate, 65.7% required at least one biologic DMARD to control uveitis. Younger age at JIA onset, polyarticular course, and a history of systemic steroid use were identified as independent predictors of MTX failure — defining a high-risk population in need of earlier or alternative therapeutic strategies.

• Patients at risk of oligoarthritis-to-polyarticular extension: Early stratification of oligoarthritis patients who will progress to polyarticular disease remains an active area of investigation. Novel immune biomarkers — including elevated CD3:CD14 ratios, HLA-DR+ T cell subsets, effector memory CD4+ and CD8+ proportions, and extracellular vesicle surface markers in synovial fluid and peripheral blood — have demonstrated discriminatory performance (AUC up to 1.0 in combined models), underscoring the need for validated prognostic tools to guide targeted, pre-emptive therapy.

• Refractory uveitis in polyarticular JIA patients: Children with chronic non-infectious uveitis inadequately controlled on biweekly adalimumab represent a population with limited escalation options. Weekly adalimumab demonstrated promising efficacy, with 80% of patients showing no active anterior inflammation at last follow-up, and enabling complete oral corticosteroid withdrawal in five of seven treated patients — yet this approach remains under-studied in formal trials.

• Growth-impaired children with active polyarticular disease: Growth retardation, reported at an incidence of 8% to 41% in JIA, is most severe in systemic and polyarticular subtypes. Chronic inflammation, prolonged glucocorticosteroid use, and disruption of the GH/IGF1 axis contribute to growth stunting and pubertal delays, yet comprehensive auxological screening protocols and data on systemic hormonal resistance in JIA remain insufficient.

• Infants and very young children with early-onset polyarticular disease: Infant-onset JIA is frequently diagnosed late — with a median time from symptom onset to first rheumatology consultation of 3.1 months versus 2.3 months in toddler-onset JIA — and carries significantly higher disease activity at follow-up (cJADAS10: 3.0 vs 2.1). This population requires improved clinical awareness and earlier initiation of effective DMARDs to reduce long-term consequences.

• Patients transitioning to adult care with active or complicated disease: At the time of transition to adult rheumatology, 46% of JIA-associated uveitis patients had developed ocular complications, over half had experienced five or more uveitis flares since diagnosis, and 53% required biologic DMARDs — reflecting the substantial residual burden carried into adulthood and the need for structured, continuous multidisciplinary follow-up across the transition period.

SELECT-YOUTH Data Supporting RINVOQ's EC Approval

Recent clinical evidence across polyarticular JIA spans imaging, biologic efficacy, and safety surveillance, offering clinical and strategic teams a multi-dimensional view of treatment outcomes in this population.

RINVOQ's Role in the Evolving pJIA Treatment Landscape

Over the past five years, the treatment landscape for active polyarticular juvenile idiopathic arthritis (pJIA) has been shaped by a combination of refined dosing strategies for established biologics and the emergence of targeted small-molecule therapies. Subcutaneous formulations have gained particular traction: population pharmacokinetic and exposure-response analyses confirmed that weight-tiered subcutaneous abatacept dosing provides near-maximal efficacy and is clinically comparable to intravenous regimens in patients with pJIA aged 2–17 years, with trough concentration identified as the best exposure predictor for JIA-ACR responses. Similarly, long-term extension data for subcutaneous tocilizumab demonstrated sustained disease control over up to 5 years, with tocilizumab trough concentrations maintained at mean values of approximately 10 μg/mL in pJIA patients, and inactive disease reported in 90% of patients weighing <30 kg and 53% of those weighing ≥30 kg per American College of Rheumatology provisional criteria.

The role of Janus kinase (JAK) inhibitors has expanded meaningfully within this period. Interim data from an ongoing long-term extension study of tofacitinib in patients with JIA (aged 2 to <18 years) showed JIA-ACR70 and JIA-ACR90 response rates of 60.0% and 33.6%, respectively, at month 1 among patients with polyarticular course JIA, with efficacy generally improving over time and inactive disease (JADAS27 ≤1.0) achieved in 46.8% of patients at month 48. Safety findings were consistent with the known tofacitinib profile, with serious adverse events in 15.1% of patients and serious infections in 10. In the TNF inhibitor space, a prospective randomized comparison of etanercept and adalimumab in 66 pJIA patients demonstrated that both agents produced statistically significant reductions in inflammatory markers and disease activity scores over 6 months, with adalimumab showing faster onset at 1–3 months but no significant difference in efficacy or safety profiles at 6 months.

Extrapolation frameworks have also matured as a methodological pillar supporting pJIA drug development. Systematic exposure and response comparisons across registration trials for infliximab, tocilizumab, golimumab, and adalimumab demonstrated that, when exposures are matched, pJIA response is similar to or higher than adult rheumatoid arthritis response for the majority of biologic subcomponents evaluated — providing a validated basis for pharmacokinetic exposure-matching as a regulatory extrapolation strategy. Collectively, these developments reflect a landscape increasingly defined by subcutaneous and oral administration options, weight-based precision dosing, and a growing evidence base supporting long-term disease control across multiple mechanistic classes.

Understanding RINVOQ's Safety Profile in pJIA and Beyond

Upadacitinib's safety profile has been characterized across a broad range of inflammatory indications — including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and several others — through both randomized controlled trials and real-world observational studies. Across these settings, the overall tolerability profile has been described as favorable, with no new safety risks emerging with longer-term exposure.

• Infections, including herpes zoster, represent the most consistently observed safety signal. Rates of herpes zoster and opportunistic infections were higher with upadacitinib versus adalimumab in psoriatic arthritis trials. In the Japanese RA population, herpes zoster rates were notably elevated (7.8, 12.4, and 16.7 per 100 patient-years with 7.5 mg, 15 mg, and 30 mg, respectively) compared with global populations (3.7 and 7.0 per 100 patient-years with 15 mg and 30 mg, respectively), with prior herpes zoster identified as a significant risk factor. Across dermatology-focused literature, herpes simplex and herpes zoster infections were associated with upadacitinib, particularly at high doses.

• Dose-dependent adverse events have been observed, particularly at the 30 mg dose. In the integrated PsA safety analysis, serious infections, anemia, and creatine phosphokinase (CPK) elevations were most frequent with upadacitinib 30 mg. In the ulcerative colitis phase 2b trial, increases in serum lipid levels and CPK were observed across upadacitinib dose groups. Upper respiratory tract infection, nasopharyngitis, and increased CPK were the most common treatment-emergent adverse events overall.

• Rates of major adverse cardiovascular events (MACEs), venous thromboembolism (VTE), malignancies, and deaths were comparable between upadacitinib and adalimumab in the integrated PsA analysis. A meta-analysis of 4 RCTs in RA (4,201 patients) found no statistically significant differences between upadacitinib and control groups in total VTE (0.79% vs. 0.78%; RR=0.93, 95% CI: 0.47–1.83, P=0.82), non-fatal pulmonary embolism (RR=0.72, 95% CI: 0.28–1.83, P=0.49), or non-fatal deep vein thrombosis (RR=0.97, 95% CI: 0.32–2.96, P=0.96), though the FDA boxed warning necessitates careful patient selection.

• Gastrointestinal perforation rates did not differ significantly between JAK inhibitors (including upadacitinib) and adalimumab in a nationwide French cohort study of 39,758 patients with rheumatic diseases, with incidence rates of 2.1 (95% CI 1.5–2.8) and 1.1 (95% CI 0.8–1.5) per 1,000 person-years, respectively (weighted HR 1.1, 95% CI 0.7–1.9; P=0.65).

• In off-label dermatologic use, overall tolerability was favorable. Across 136 articles covering 204 patients treated with oral JAK inhibitors (including upadacitinib), adverse events were reported in a minority of patients and were predominantly described as mild and transient. Dose reduction or treatment discontinuation did not lead to immediate relapse in many cases.

• Real-world data from a university hospital cohort of 64 patients receiving JAK inhibitors for rheumatic diseases (including 27 on upadacitinib) reported adverse effects in 26.56% of patients overall, comprising one SARS-CoV-2 case, one basal cell carcinoma, and two herpes zoster cases. No cardiovascular or thromboembolic events were recorded in that cohort.

Upadacitinib's EC Approval: A Strategic Leap in Pediatric JIA

The European Commission's approval of upadacitinib (RINVOQ) for active polyarticular juvenile idiopathic arthritis (pJIA) marks a pivotal moment for pediatric rheumatology. For children aged two years and older who have not responded adequately to conventional DMARDs, this oral JAK inhibitor offers a new therapeutic avenue. The introduction of a 1 mg/mL oral solution, alongside the existing 15 mg tablet, is particularly impactful, providing crucial flexibility for weight-based dosing and easier administration in young patients, which can be a significant factor in treatment adherence.

This regulatory decision also highlights a sophisticated approach to drug development. Efficacy for pJIA was successfully extrapolated from adult rheumatoid arthritis data, a strategy supported by robust pharmacokinetic matching and exposure-response modeling. This scientific rigor, combined with interim safety and efficacy data from the SELECT-YOUTH study showing high PedACR responses and a safety profile consistent with known upadacitinib data, underscores a pathway for bringing innovative treatments to pediatric populations more efficiently.

However, the landscape for pJIA treatment is competitive. Existing biologics like etanercept, adalimumab, and tocilizumab have demonstrated comparable efficacy and are well-established, with etanercept often being a first-line choice. While RINVOQ's oral route offers convenience, the long-term safety profile in this vulnerable pediatric population will require ongoing vigilance, especially considering the potential for serious adverse events observed with other JIA treatments. Furthermore, ensuring consistent adherence to a daily oral regimen in children, even with a palatable solution, presents a real-world challenge that could influence overall treatment effectiveness. This approval positions upadacitinib as a strong contender, but its ultimate impact will depend on how it navigates these clinical and market dynamics.